Literature DB >> 26159805

Leukoplakia, Oral Cavity Cancer Risk, and Cancer Survival in the U.S. Elderly.

Elizabeth L Yanik1, Hormuzd A Katki2, Michael J Silverberg3, M Michele Manos3, Eric A Engels2, Anil K Chaturvedi2.   

Abstract

Screening for oral leukoplakia, an oral cavity cancer (OCC) precursor, could lead to earlier detection of OCC. However, the progression rate from leukoplakia to OCC and the benefits of leukoplakia screening for improving OCC outcomes are currently unclear. We conducted a case-cohort study of U.S. adults ages ≥65 years in the Surveillance, Epidemiology, and End Results (SEER)-Medicare linkage. We identified leukoplakia diagnoses through Medicare claims, and OCC diagnoses through SEER cancer registries. Weighted Cox regression was used to estimate leukoplakia associations with OCC incidence, and the absolute OCC risk following leukoplakia diagnosis was calculated. Among OCC cases, we compared OCC stage and OCC survival between cases with a prior leukoplakia diagnosis versus those without prior leukoplakia. Among 470,266 individuals in the SEER-Medicare subcohort, 1,526 (0.3%) had a leukoplakia diagnosis. Among people with leukoplakia, the cumulative OCC incidence was 0.7% at 3 months and 2.5% at 5 years. OCC risk was most increased <3 months after leukoplakia diagnosis (HR, 115), likely representing the diagnosis of prevalent cancers. Nonetheless, risk remained substantially increased in subsequent follow-up [HR ≥ 3 months, 24; 95% confidence interval (CI), 22-27; HR ≥ 12 months, 22, 95% CI, 20-25]. Among OCC cases (N = 8,927), those with prior leukoplakia were less likely to be diagnosed at regional/distant stage (OR, 0.36; 95% CI, 0.30-0.43), and had lower mortality (HR, 0.74; 95% CI, 0.65-0.84) when compared with OCC cases without a prior leukoplakia. Individuals with leukoplakia have substantially elevated risk of OCC. Lower stage and better survival after OCC diagnosis suggest that leukoplakia identification can lead to earlier OCC detection and reduced mortality. ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Year:  2015        PMID: 26159805      PMCID: PMC4560597          DOI: 10.1158/1940-6207.CAPR-15-0091

Source DB:  PubMed          Journal:  Cancer Prev Res (Phila)        ISSN: 1940-6215


  22 in total

1.  Development of squamous cell carcinoma from pre-existent oral leukoplakia: with respect to treatment modality.

Authors:  T Saito; C Sugiura; A Hirai; K Notani; Y Totsuka; M Shindoh; H Fukuda
Journal:  Int J Oral Maxillofac Surg       Date:  2001-02       Impact factor: 2.789

2.  Potentially malignant oral lesions in northern Ireland: a 20-year population-based perspective of malignant transformation.

Authors:  C G Cowan; T A Gregg; S S Napier; S M McKenna; F Kee
Journal:  Oral Dis       Date:  2001-01       Impact factor: 3.511

3.  The assessment of lead time and length bias in the evaluation of screening programmes.

Authors:  N E Day
Journal:  Maturitas       Date:  1985-05       Impact factor: 4.342

4.  Malignant transformation in 1458 patients with potentially malignant oral mucosal disorders: a follow-up study based in a Taiwanese hospital.

Authors:  Shue-Sang Hsue; Wen-Chen Wang; Chung-Ho Chen; Cheng-Chung Lin; Yuk-Kwan Chen; Li-Min Lin
Journal:  J Oral Pathol Med       Date:  2007-01       Impact factor: 4.253

5.  Effect of screening on oral cancer mortality in Kerala, India: a cluster-randomised controlled trial.

Authors:  Rengaswamy Sankaranarayanan; Kunnambath Ramadas; Gigi Thomas; Richard Muwonge; Somanathan Thara; Babu Mathew; Balakrishnan Rajan
Journal:  Lancet       Date:  2005 Jun 4-10       Impact factor: 79.321

6.  Long-term treatment outcome of oral premalignant lesions.

Authors:  P Holmstrup; P Vedtofte; J Reibel; K Stoltze
Journal:  Oral Oncol       Date:  2005-11-28       Impact factor: 5.337

7.  Oral leukoplakia and malignant transformation. A follow-up study of 257 patients.

Authors:  S Silverman; M Gorsky; F Lozada
Journal:  Cancer       Date:  1984-02-01       Impact factor: 6.860

Review 8.  Prognosis of oral pre-malignant lesions: significance of clinical, histopathological, and molecular biological characteristics.

Authors:  Jesper Reibel
Journal:  Crit Rev Oral Biol Med       Date:  2003

9.  Nomenclature and classification of potentially malignant disorders of the oral mucosa.

Authors:  S Warnakulasuriya; Newell W Johnson; I van der Waal
Journal:  J Oral Pathol Med       Date:  2007-11       Impact factor: 4.253

10.  Malignant transformation of oral leukoplakia: a follow-up study of a hospital-based population of 166 patients with oral leukoplakia from The Netherlands.

Authors:  K P Schepman; E H van der Meij; L E Smeele; I van der Waal
Journal:  Oral Oncol       Date:  1998-07       Impact factor: 5.337

View more
  13 in total

Review 1.  Prognostic factors, predictive markers and cancer biology: the triad for successful oral cancer chemoprevention.

Authors:  Jose Augusto Monteiro de Oliveira Novaes; William N William
Journal:  Future Oncol       Date:  2016-06-22       Impact factor: 3.404

Review 2.  Screening for Cancer in Persons Living with HIV Infection.

Authors:  James J Goedert; H Dean Hosgood; Robert J Biggar; Howard D Strickler; Charles S Rabkin
Journal:  Trends Cancer       Date:  2016-08

3.  Cancer risk among the HIV-infected elderly in the United States.

Authors:  Elizabeth L Yanik; Hormuzd A Katki; Eric A Engels
Journal:  AIDS       Date:  2016-06-19       Impact factor: 4.177

4.  Oral Leukoplakia and Risk of Progression to Oral Cancer: A Population-Based Cohort Study.

Authors:  Anil K Chaturvedi; Natalia Udaltsova; Eric A Engels; Jed A Katzel; Elizabeth L Yanik; Hormuzd A Katki; Mark W Lingen; Michael J Silverberg
Journal:  J Natl Cancer Inst       Date:  2020-10-01       Impact factor: 13.506

5.  The Microbiome of Potentially Malignant Oral Leukoplakia Exhibits Enrichment for Fusobacterium, Leptotrichia, Campylobacter, and Rothia Species.

Authors:  Abdrazak Amer; Sheila Galvin; Claire M Healy; Gary P Moran
Journal:  Front Microbiol       Date:  2017-12-01       Impact factor: 5.640

6.  Sex differences in patients with high risk HPV-associated and HPV negative oropharyngeal and oral cavity squamous cell carcinomas.

Authors:  Hong Li; Henry S Park; Heather A Osborn; Benjamin L Judson
Journal:  Cancers Head Neck       Date:  2018-06-20

7.  Favorable Lip and Oral Cancer Mortality-to-Incidence Ratios in Countries with High Human Development Index and Expenditures on Health.

Authors:  Wen-Wei Sung; Yong-Chen Hsu; Chen Dong; Ying-Ching Chen; Yu-Chi Chao; Chih-Jung Chen
Journal:  Int J Environ Res Public Health       Date:  2021-06-03       Impact factor: 3.390

Review 8.  The role of teledentistry in oral cancer patients during the COVID-19 pandemic: an integrative literature review.

Authors:  Helbert Eustáquio Cardoso da Silva; Glaucia Nize Martins Santos; André Ferreira Leite; Carla Ruffeil Moreira Mesquita; Paulo Tadeu de Souza Figueiredo; Paula Elaine Diniz Dos Reis; Cristine Miron Stefani; Nilce Santos de Melo
Journal:  Support Care Cancer       Date:  2021-07-05       Impact factor: 3.359

9.  Considerations in the evaluation and management of oral potentially malignant disorders during the COVID-19 pandemic.

Authors:  Rabie M Shanti; Eric T Stoopler; Gregory S Weinstein; Jason G Newman; Steven B Cannady; Karthik Rajasekaran; Takako I Tanaka; Bert W O'Malley; Anh D Le; Thomas P Sollecito
Journal:  Head Neck       Date:  2020-05-16       Impact factor: 3.147

Review 10.  Chemoprevention of Head and Neck Cancers: Does It Have Only One Face?

Authors:  Krzysztof Siemianowicz; Wirginia Likus; Mariola Dorecka; Renata Wilk; Włodzimierz Dziubdziela; Jarosław Markowski
Journal:  Biomed Res Int       Date:  2018-09-25       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.